Pharma fail: Concordia pulls bond as M&A flounders

With pharma firms under intense scrutiny in the US, Concordia Healthcare Corp has dropped a planned $950m bond for its $3.5bn acquisition of Amdipharm Mercury, as the debt financing encountered some resistance from investors. Max Bower reports.